Saved Results

No results saved yet.

Enter a patient name and hit Save on a result.

Clinical calculator summary

HCT-CI (Transplant Risk)

The HCT-CI (Sorror Score) predicts non-relapse mortality (NRM) and survival after allogeneic hematopoietic cell transplantation.

Evidence-based context for fast calculator use

Purpose:
HCT-CI (Sorror Score) quantifies comorbidity burden to stratify non-relapse mortality risk before allogeneic hematopoietic cell transplantation.
Population:
patients with the specific hematologic diagnosis and disease phase described by the model
Factors:
Pulmonary: Moderate/Severe?, Arrhythmia?, Cardiac?, Heart Valve Disease?, Inflammatory Bowel Disease?, Diabetes / Endocrine?, Cerebrovascular Disease?, Psychiatric Disturbance?
Reference:
Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106(8):2912-2919.
HomeHCT-CI (Transplant Risk)
Pin your most used calculators here by clicking the star in the dropdown.

HCT-CI (Transplant Risk)

Clinical Context & Background

The HCT-CI (Sorror Score) predicts non-relapse mortality (NRM) and survival after allogeneic hematopoietic cell transplantation. It sums weighted comorbidities to stratify transplant risk.
Primary Source EvidenceSorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106(8):2912-2919.
Formula Logic
Sum of weighted comorbidities (1-3 points each).

Reference Data

ScoreRisk Group2-Year NRM Estimate
0Low Risk14%
1 - 2Intermediate Risk21%
≥ 3High Risk41%

Clinical Workflow

Use, Interpret, And Continue The Patient Pathway

Expand for workflow guidance, limitations, examples, and related next steps.

When To Use

  • Use HCT-CI (Transplant Risk) when hCT-CI (Sorror Score) quantifies comorbidity burden to stratify non-relapse mortality risk before allogeneic hematopoietic cell transplantation.
  • Confirm that the patient, diagnosis, disease phase, and available inputs match the cited model before calculation.

How To Interpret

  • Interpret the displayed result using the calculator-specific formula and reference table, spanning 0 through ≥ 3.
  • A boundary result should prompt input verification and clinical review rather than false precision.

What To Do Next

  • Confirm morphology, molecular/cytogenetic data, treatment timing, laboratory units, and the current disease-specific guideline before acting.
  • Document the inputs, result, timing, and clinical context so the assessment can be reproduced.

Limitations

  • Hematology scores are diagnosis-, phase-, and treatment-specific and should not be transferred between diseases.
  • The result supports clinician judgment and does not independently determine treatment.

Validated Population

patients with the specific hematologic diagnosis and disease phase described by the model

How to apply this result

For a representative case, verify Pulmonary: Moderate/Severe?, Arrhythmia?, Cardiac?, calculate the result, and confirm that its classification matches the highlighted reference band before continuing the disease-specific pathway.

Hematology hubContinue to related calculators and clinical workflow resources.

Share This Calculator

Share:

Related Tools

NCCN-IPI (Lymphoma)CLL-IPIMIPI (Mantle Cell Lymphoma)

Frequently Asked Questions

When should HCT-CI (Transplant Risk) be used?

Use it for patients with the specific hematologic diagnosis and disease phase described by the model when all required inputs and the intended clinical setting are confirmed.

Can HCT-CI (Transplant Risk) determine treatment by itself?

No. Interpret the result with the cited evidence, complete clinical assessment, current guidelines, and patient-specific goals.

Evidence-based oncology decision support. Verify with clinical guidelines.